AUTL
Autolus Therapeutics
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 627.00M; Volume: 74.57K; AvgVol 3m: 157.95K; Beta: –;
Cost estimate:
P/E: –; EPS: -2.78; EPS growth quarter/prev quarter: 5.70%;
EPS growth this year: -448.30%; EPS growth past 5 years: ;
EPS ttm: -2.74;
P/S: 552.11; P/B: 2.43; P/Cashflow: 3.13; P/FCF: ;
Sales: 1.24M; Sales growth quarter/prev quarter: 0.00%; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -41.10%; ROE – return on equity: -48.60%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 26.63%; Insider Transactions:0.00%;
Institutional Ownership: 29.40%; Institutional Transactions: -9.07%;
Data update: 07/10/2020.